Conditions

Free potential treatment lowers blood sugars, helps with weight loss, drops blood pressure and cholesterol, and may add at least 10 years of quality of life.

First oral GLP-1 agonist undergoing Phase 3 trials shows significant benefits managing type 2 diabetes.

Study looks at convenient once-weekly GLP-1 that can reduce chances of heart attacks and strokes.

Recommendations place special emphasis on youth newly diagnosed with diabetes.

A1c management over longer periods shown to decrease likelihood of diagnosis.

Researchers suggest implementation of cardioprotective medications sooner than current guideline recommendations.

Researchers study efficacy and safety of GLP-1 inhibitors on weight loss.

New study focuses on cardiovascular safety of weight loss drug in patients with excess weight or obesity.

The SUMMIT VIP study shows conventional risk factors do not suffice in predicting heart complications.

Patient is male, 48 years of age, type 2 diabetes with hyperglycemia for eight years, class III obesity,  and very symptomatic GERD. Patient planned to have laparoscopic sleeve gastrectomy. I asked him why he chose that particular surgery. He said, "Because it's less invasive." I asked if his surgeon told him the sleeve gastrectomy could increase his GERD, and is not as effective for the treatment of type 2 diabetes nor for weight loss as is a bypass. He said, "No, the surgeon just left it to my choice. I said I wanted the sleeve and he was good with that."